Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
41 hedge funds and large institutions have $38.9M invested in Bellerophon Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
11% more funds holding
Funds holding: 37 → 41 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
18% less capital invested
Capital invested by funds: $47.3M → $38.9M (-$8.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$1.28M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$401K |
| 3 |
Two Sigma Investments
New York
|
+$338K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$330K |
| 5 |
State Street
Boston,
Massachusetts
|
+$315K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.24M |
| 2 |
Renaissance Technologies
New York
|
-$586K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$495K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$271K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$207K |
BLPH Hedge Fund Activity: Q3 2020 in Review
41 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2020, worth a combined $38.9M — down 18% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BLPH positions and 7 closed out — a net gain of 4 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Wells Fargo, adding an estimated $1.28M. The largest seller was Boxer Capital, exiting entirely with an estimated $1.24M sold.
- 41 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2020, up from 37 in Q2 2020.
- Funds reported $38.9M of Bellerophon Therapeutics, Inc. stock for Q3 2020, down 18% quarter-over-quarter.
- 11 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2020 and 7 closed out, a net change of +4 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q3 2020 was Wells Fargo, an estimated $1.28M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q3 2020 was Boxer Capital, an estimated $1.24M sold.
Based on aggregated 13F filings for Q3 2020.